Connect to other sites within the UBM Medica Network
Even Those With Susceptibility Genes Can Lower Breast Cancer Risk
People who carry a germline breast cancer susceptibility mutation can still substantially lower their risk of developing breast cancer, according to a new study.
Arsenic in Drinking Water Linked to Uptick in Bladder Cancer?
The higher incidence of bladder cancer in the Northeast in the last 50 years may be attributed to the presence of arsenic in the drinking water, according to a new study.
UK Trial Suggests Benefit, Parameters for Lung Cancer Screening Program
The UK Lung Cancer Screening Trial found that a low-dose CT screening program targeting high-risk individuals can find lung cancer at early stages.
Adding ADT Fails to Improve Survival in Favorable Intermediate-Risk Prostate Cancer
The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.
ASCO Releases Resource-Stratified Invasive Cervical Cancer Guidelines
ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
Total Body Irradiation Did Not Improve Response of Adoptive Cell Transfer
Adding total body irradiation to chemotherapy prior to the adoptive cell transfer of TILs had no effect on tumor regression in patients with metastatic melanoma.
Disparities Still Exist for HCC Incidence, Survival in United States
A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.